machineMD advances to phase 2 of DayOne Health 4.0 Accelerator

The DayOne Health 4.0 Accelerator supports early to mid-stage digital health startups providing solutions from diagnostics to patient communication and healthcare professional support. Selected startups receive personalized coaching, access to the DayOne network, innovation spaces, and enhanced visibility - all without equity requirements or fees.

For the first phase of the 2023 edition, the accelerator has welcomed 15 startups including four Swiss startups that stood out among 109 applications from 35 countries. Out of these 15, five companies advanced to the second phase, based on their strong value proposition for different stakeholders involved in clinical trials, the pharmaceutical industry, healthcare professionals (HCPs) and patients, among others. They have also convinced the DayOne team by showing significant progress over Phase 1 of the program (Sept-Nov 2023) and exhibiting their readiness to get involved in collaborations and partnerships, in particular with biopharma companies.

Martin Jordan, Basel Area Business & Innovation’s media and PR manager expresses his enthusiasm, “This year’s DayOne Health 4.0 Accelerator edition revolves around clinical trials and ventures harnessing AI, data and digital tools to power clinical development and healthcare delivery. Four main focus areas have been identified: (1) Reinventing clinical trials by optimizing patient identification, access, and enrolment. (2) Advancing clinical development by harnessing data and clinical tools to improve endpoints. (3) Simplifying operations by streamlining clinical operations and workflow management. (4) And enhancing patient experience by prioritizing patient experience to boost outcomes.”

The goal of the program’s second phase is to offer continued support for the five selected finalists through 1:1 mentoring, expert exchanges, introduction to relevant stakeholders in the healthcare ecosystem, and additional services to get the startups ready for collaborations at the interface with the pharma industry.

Among the startups proceeding to the second phase is Bernese medtech company machineMD. Founded at the University Hospital of Bern in 2019, machineMD focuses on delivering standardized and automated medical examinations to enable fast, accurate and early diagnosis of neurological disorders. Its flagship device, neos®, uses advanced VR technology to assess eye movements and pupillary function for better brain function measurement. It’s a Class I medical device in Switzerland and the UK, with plans to introduce it as a Class II(a) device in the USA. With the continued support by the DayOne Health 4.0 Accelerator experts, machineMD is on the right path to grow and expand its business.

Other finalists included the startup Briya from Israel, CliniNote from Poland, FindMeCure/TrialHub based in Bulgaria and Italian startup InSilicoTrials Technologies.

(SR)